AstraZeneca looking outside for drugs

AstraZeneca has trailed rivals such as Novartis and Pfizer in its willingness to purchase promising drugs that were discovered outside their own laboratories, and the drugmaker now is playing catch-up. Over the past few months AstraZeneca has signed several deals totaling up to $1.6 billion to license drug candidates and may be considering additional alliances.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ